Financials

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

04-29	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/10/25	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
29/04/25	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/04/25	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
29/04/24	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/04/23	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/07/22	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
11/04/22	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/04/21	Global markets live: Daimler, GSK, Mattel
23/12/20	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/09/20	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
29/07/18	Eurofins Cerep SA acquired KVI-Plusz.	CI
03/08/15	Eurofins Cerep SA and Jean-Louis Oger, along with the members of the current leadership of Bioaccess, completed the acquisition of a majority stake in Bioaccess S.A.	CI

18/09/25	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
12/04/23	Eurofins Cerep : annonce ses résultats 2022	PU

04-10	Eurofins Cerep : annonce ses résultats 2025
01/10/25	Eurofins Cerep : Rapport Financier Semestriel - Semestre clos le 30 juin 2025
09/05/25	Eurofins Cerep : Rapport annuel 2024
03/04/25	Eurofins Cerep : annonce ses résultats du 1er semestre 2023
03/04/25	Eurofins Cerep : annonce ses résultats 2024

Director	Title	Age	Since
Rodolphe Simonot BRD	Director/Board Member	-	-
Paul Ratcliffe CHM	Chairman	-	10/08/2023
Damien Vielliard BRD	Director/Board Member	-	22/05/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EUROFINS-CEREP	+0.01%	+4,900.50%	-	-	99.24M
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+1.96%	+5.82%	+79.92%	+120.30%	27.3B
Weighted average by Cap.	+2.07%	+6.53%	+90.75%	+137.74%